Forum Navigation
Please or Register to create posts and topics.

KX-826 / Pyrilutamide Phase III Trial Starts

This is exciting news. Phase 1 and 2 trials are already complete and the phase 3 trial should be the last stage before KX-826 is available commercially. Obviously there has been a lot of disappointments with new drugs over the years, but this one looks promising.

What KX-826 is:

"KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of androgenetic alopecia (AGA) and acne vulgaris."

It's a topically-applied treatment that binds to androgen receptors in the hair follicles, effectively blocking DHT from binding and causing hair loss.

This is a different mechanism to finasteride/Propecia, for example, which works by lowering DHT levels altogether. While this mechanism works to stop hair loss, DHT has effects elsewhere in the body (besides the scalp) and so lowering it systemically can cause side effects in some people. In theory, KX-826 will avoid this problem: It will block the effects of DHT locally where it is applied without altering total DHT levels.

When the trial will be completed:

We look forward to completing the planned 416 subjects enrollment by June 2022, and the follow-up medical evaluation (6 months study + 1 month follow-up) within the year. With the goal of completing the phase III clinical trial this year, we are speeding up the process and expecting that KX-826 would benefit global patients as soon as possible."

So, if all goes well, KX-826 could be available by mid 2023 (although this is a best-case scenario).

How effective is KX-826?

There's not much information on how effective KX-826 is at the moment. But you have to suspect it's at least as effective as something like finasteride (but with lower chance of side effects) otherwise they probably wouldn't bother progressing further with the trials.

What do you think? Will we finally have a new hair loss drug soon?

Kintor has released the following powerpoint that contains further details on KX-826/Pyrilutamide:

We should have some idea of how effective this drug will be when phase 2 data is released in June this year (see page 34).


Uploaded files:
  • pyri.png